AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11818027 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT) with a dose of 12-15 Gy (median 15 Gy) followed by postoperative external radiation therapy (EXRT) with a median total dose of 60 Gy.
Number of subjects: 32
Study 11818027 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with postoperative external radiation therapy (EXRT) alone.
Number of subjects: 32
Study 10723515 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine plus stavudine plus hydroxyurea
Number of subjects: 144
Study 10723515 — intervention group
Group type: COMPARATOR
Intervention: Didanosine plus stavudine
Number of subjects: 144
Study 7864328 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 7.5 micrograms.kg‐1 on induction of anaesthesia, followed by alfentanil 7.5 micrograms.kg‐1 90 s before surgical incision (group A)
Number of subjects: 60
Study 7864328 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 15 micrograms.kg‐1, 10 min after abdominal incision (group B)
Number of subjects: 60
Study 2376428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan-salbutamol combination tablet (Redol comp)
Number of subjects: 10
Study 2376428 — intervention group
Group type: COMPARATOR
Intervention: Plain dextromethorphan tablet (Extuson)
Number of subjects: 10
Study 14503 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (2.0 g total dosage over 48 hours)
Number of subjects: 44
Study 14503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 14503 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 44
Study 31997647 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted alternating treatments design
Number of subjects: 0
Study 31997647 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative methods (e.g., random assignment)
Number of subjects: 0
Study 31301748 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing frame programme plus usual care
Number of subjects: 140
Study 31301748 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 28454792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once-weekly (EQW)
Number of subjects: 14752
Study 28454792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14752
Study 26120790 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel
Number of subjects: 47
Study 26120790 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 47
Study 23531167 — intervention group
Group type: EXPERIMENTAL
Intervention: AdWords campaign based on keywords related to 'Eastenders' and 'cervical cancer'
Number of subjects: 10
Study 23531167 — intervention group
Group type: COMPARATOR
Intervention: Control group (ten practices not using the AdWords campaign)
Number of subjects: 10
Study 21752951 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal group A conjugate (PsA‐TT)
Number of subjects: 0
Study 21752951 — intervention group
Group type: COMPARATOR
Intervention: 1/5 dose of Meningococcal ACWY polysaccharide (PsACWY)
Number of subjects: 0
Study 19710585 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based sore throat clinic program with free nurse-observed oral penicillin treatment of group A streptococcal pharyngitis
Number of subjects: 22000
Study 19710585 — intervention group
Group type: COMPARATOR
Intervention: Routine general practice care (Control)
Number of subjects: 22000
Study 22852485 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 2 hours with intermittent exercise at a DEP mass concentration near 100 microg/m3
Number of subjects: 30
Study 22852485 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 30
Study 22852485 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2) exposure near 0.35 ppm
Number of subjects: 30
Study 16433278 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic attribution
Number of subjects: 0
Study 16433278 — intervention group
Group type: COMPARATOR
Intervention: Control (no genetic attribution)
Number of subjects: 0
Study 12890841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose bevacizumab (10 mg/kg every two weeks)
Number of subjects: 116
Study 12890841 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bevacizumab (3 mg/kg every two weeks)
Number of subjects: 116
Study 12890841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 12890841 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 116
Study 10199350 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal-cord stimulation in addition to best medical treatment
Number of subjects: 120
Study 10199350 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 120
Study 7766296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose OKT3 (0.5 mg twice daily)
Number of subjects: 22
Study 7766296 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose OKT3 (5 mg daily)
Number of subjects: 22
Study 2279744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide using medicated plastic porous tape (8 micrograms/cm2)
Number of subjects: 18
Study 2279744 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide using 0.025% cream
Number of subjects: 18
Study 7437907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen 2 mg (single oral dose)
Number of subjects: 20
Study 7437907 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (dosage not specified)
Number of subjects: 20
Study 7437907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg twice daily for 4 days
Number of subjects: 20
Study 7437907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7437907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen 0.5 mg 3 times daily for 12 days
Number of subjects: 20
Study 29790790 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 40
Study 29790790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28641315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen: 4 cycles of epirubicin 90 mg/m² followed by 4 cycles of docetaxel 75 mg/m²
Number of subjects: 658
Study 28641315 — intervention group
Group type: COMPARATOR
Intervention: Concurrent regimen: 6 cycles of epirubicin 75 mg/m² plus docetaxel 75 mg/m²
Number of subjects: 658
Study 25740027 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cut method (cast bivalve and Ace wrap)
Number of subjects: 45
Study 25740027 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-cut method (cast bivalve, spread, and Ace wrap)
Number of subjects: 45
Study 25740027 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-cut method (cast bivalve, spread, Webril cut, and Ace wrap)
Number of subjects: 45
Study 25740027 — intervention group
Group type: COMPARATOR
Intervention: Ace wrap after cast cutting
Number of subjects: 45
Study 24617000 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (standardized allergen vaccine)
Number of subjects: 136
Study 21411156 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811
Study 21411156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study 19146133 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with Clearfil New Bond
Number of subjects: 90
Study 19146133 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with Xeno III
Number of subjects: 90
Study 19146133 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with AdheSE
Number of subjects: 90
Study 19146133 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposen with Clearfil New Bond
Number of subjects: 90
Study 16565866 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (n = 18)
Number of subjects: 44
Study 16565866 — intervention group
Group type: COMPARATOR
Intervention: Placebo-CPAP (<1 cm H2O) (n = 10)
Number of subjects: 44
Study 16565866 — intervention group
Group type: COMPARATOR
Intervention: Supplemental nocturnal oxygen (3 l/min) (n = 16)
Number of subjects: 44
Study 14601199 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ml 0.75% ropivacaine (18.75 mg)
Number of subjects: 40
Study 14601199 — intervention group
Group type: COMPARATOR
Intervention: 3 ml 0.75% ropivacaine (22.5 mg)
Number of subjects: 40
Study 10991865 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of racemic dOTC
Number of subjects: 6
Study 10991865 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of racemic dOTC
Number of subjects: 6
Study 10991865 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of racemic dOTC
Number of subjects: 6
Study 10991865 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of racemic dOTC
Number of subjects: 6
Study 10991865 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg of racemic dOTC
Number of subjects: 6
Study 10991865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8854777 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hepatic artery infusion of 5-FU (500 mg x 4 days/week for six weeks from 2 weeks after surgery)
Number of subjects: 18
Study 8854777 — intervention group
Group type: COMPARATOR
Intervention: Oral 5-FU from 2 weeks after surgery
Number of subjects: 18
Study 1296454 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 at a dose of 3 million IU subcutaneously twice/daily for 6 days/week for 4 weeks
Number of subjects: 30
Study 1296454 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 once/daily in the evening
Number of subjects: 30
Study 1296454 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 once/daily plus MLT at 10 or at 50 mg/day
Number of subjects: 30
Study 1296454 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 30
Study 1296454 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 given twice/daily
Number of subjects: 30
Study 1296454 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus MLT
Number of subjects: 30
Study 1296454 — intervention group
Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 30
Study 6084924 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Number of subjects: 54
Study 6084924 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Number of subjects: 54
Study 30022567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) for 8 weeks
Number of subjects: 39
Study 30022567 — intervention group
Group type: COMPARATOR
Intervention: Psychopharmacological consultation
Number of subjects: 39
Study 26655493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl (1 μg/kg)
Number of subjects: 21
Study 26655493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (10 μg/kg)
Number of subjects: 21
Study 24371300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antioxidant therapy (mixed tocopherols 666 IU/d plus α-lipoic acid 600 mg/d)
Number of subjects: 353
Study 24371300 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 353
Study 22770692 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA) as a supplement to general anesthesia
Number of subjects: 60
Study 22770692 — intervention group
Group type: COMPARATOR
Intervention: Conventional general anesthesia
Number of subjects: 60
Study 22770692 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (HTEA)
Number of subjects: 60
Study 20602877 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-audio eyewear (SI)
Number of subjects: 40
Study 20602877 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-audio eyewear (FI)
Number of subjects: 40
Study 20602877 — intervention group
Group type: COMPARATOR
Intervention: Normal method (SC)
Number of subjects: 40
Study 20602877 — intervention group
Group type: COMPARATOR
Intervention: Normal method (FC)
Number of subjects: 40
Study 20602877 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-audio eyewear
Number of subjects: 40
Study 18528400 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patches
Number of subjects: 60
Study 18528400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15948810 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic banding ligation
Number of subjects: 52
Study 15948810 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 52
Study 12792707 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg orally every 8 h)
Number of subjects: 40
Study 12792707 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg on the first day, 100 mg/day thereafter)
Number of subjects: 40
Study 12792707 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril-Aspirin (Captopril on the first day, followed by Aspirin)
Number of subjects: 40
Study 12792707 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin-Captopril (Aspirin on the first day, followed by Captopril)
Number of subjects: 40
Study 12147937 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based therapy
Number of subjects: 9193
Study 12147937 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based therapy
Number of subjects: 9193
Study 10189602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg)
Number of subjects: 76
Study 10189602 — intervention group
Group type: COMPARATOR
Intervention: Nortriptyline (25-100 mg)
Number of subjects: 76
Study 10189602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 76
Study 7851166 — intervention group
Group type: EXPERIMENTAL
Intervention: High anastomosis (top of anal columns)
Number of subjects: 47
Study 7851166 — intervention group
Group type: COMPARATOR
Intervention: Low anastomosis (dentate line)
Number of subjects: 47
Study 1694647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate (20 mg elemental zinc twice daily)
Number of subjects: 40
Study 1694647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 40
Study 6990674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 55
Study 6990674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg
Number of subjects: 55
Study 6990674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6990674 — intervention group
Group type: COMPARATOR
Intervention: Control (no premedication)
Number of subjects: 55
Study 31174846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg scopolamine
Number of subjects: 60
Study 31174846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg scopolamine
Number of subjects: 60
Study 31174846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31174846 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (both dosages)
Number of subjects: 60
Study 28402865 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of contralesional dorsal premotor cortex (cPMd) using repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 15
Study 28402865 — intervention group
Group type: COMPARATOR
Intervention: Standard approach involving inhibition of contralesional motor cortex (cM1)
Number of subjects: 15
Study 25661136 — intervention group
Group type: EXPERIMENTAL
Intervention: IV midazolam
Number of subjects: 156
Study 25661136 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 156
Study 23515902 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person active intervention
Number of subjects: 451
Study 23515902 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 451
Study 23515902 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater weight loss
Number of subjects: 451
Study 21332580 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine perfusion (MP)
Number of subjects: 91
Study 21332580 — intervention group
Group type: COMPARATOR
Intervention: Cold storage (CS)
Number of subjects: 91
Study 19586656 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 9319
Study 17846073 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary trunk rotation (TR)
Number of subjects: 60
Study 17846073 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary trunk rotation and half‐field eye‐patching (TR + EP)
Number of subjects: 60
Study 17846073 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (Control)
Number of subjects: 60
Study 15279521 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction counseling plus nicotine replacement therapy (NRT) plus brief advice to quit
Number of subjects: 616
Study 15279521 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational advice plus brief advice
Number of subjects: 616
Study 15279521 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 616
Study 11595291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines administration with or without therapeutic vaccination in HAART treated patients
Number of subjects: 0
Study 11595291 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination
Number of subjects: 0
Study 11595291 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment interruption (TI) or drug therapy change from a PI- to a non-nucleoside-based HAART regimen
Number of subjects: 0
Study 11595291 — intervention group
Group type: COMPARATOR
Intervention: HAART (Protease inhibitor-based)
Number of subjects: 0
Study 9625829 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (lobectomy, sleeve lobectomy, bilobectomy)
Number of subjects: 10
Study 9625829 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-grade malignant tumors group
Number of subjects: 10
Study 9625829 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative examination
Number of subjects: 10
Study 7848400 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver
Number of subjects: 38
Study 7848400 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 38
Study 3278876 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms levothyroxine (T4) daily (group I, n = 35)
Number of subjects: 74
Study 3278876 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms levothyroxine and 130.8 micrograms potassium iodide daily (group II, n = 39)
Number of subjects: 74
Study 3278876 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms iodide daily (prophylactic administration after initial treatment)
Number of subjects: 74
Study 29385323 — intervention group
Group type: COMPARATOR
Intervention: LY3016859 (LY) administered intravenously (0.1-750 mg) or subcutaneously (50 mg)
Number of subjects: 116
Study 29385323 — intervention group
Group type: COMPARATOR
Intervention: LY3016859 (LY) administered intravenously (10-750 mg)
Number of subjects: 116
Study 29385323 — intervention group
Group type: COMPARATOR
Intervention: LY3016859 (LY) administered intravenously (50-750 mg)
Number of subjects: 116
Study 29385323 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3016859 (LY)
Number of subjects: 116
Study 27721247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 1 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Number of subjects: 51
Study 27721247 — intervention group
Group type: COMPARATOR
Intervention: Dezocine 0.6 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Number of subjects: 51
Study 27721247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone group
Number of subjects: 51
Study 27721247 — intervention group
Group type: COMPARATOR
Intervention: Dezocine group
Number of subjects: 51
Study 24566612 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture
Number of subjects: 60
Study 24566612 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60
Study 24566612 — intervention group
Group type: COMPARATOR
Intervention: Control (Comparison between Manual Acupuncture and Electroacupuncture)
Number of subjects: 60
Study 22070421 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate
Number of subjects: 223
Study 22070421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 22070421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of mood disorders
Number of subjects: 223
Study 22070421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of anxiety disorders
Number of subjects: 223
Study 22070421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of substance use disorder
Number of subjects: 223
Study 20398484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 64
Study 20398484 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 64
Study 20398484 — intervention group
Group type: COMPARATOR
Intervention: Normal Control
Number of subjects: 64
Study 18547955 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU/m2 body surface area/week of r-hGH
Number of subjects: 29
Study 18547955 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU/m2 body surface area/week of r-hGH
Number of subjects: 29
Study 18547955 — intervention group
Group type: COMPARATOR
Intervention: Both doses of r-hGH
Number of subjects: 29
Study 15794968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 17137
Study 15794968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17137
Study 15128360 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 98
Study 15128360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 15128360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fiber Diet (HFD)
Number of subjects: 98
Study 11093724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 103
Study 11093724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 8881824 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind positive food challenge (DBPCFC)
Number of subjects: 15
Study 8881824 — intervention group
Group type: COMPARATOR
Intervention: Double blind negative food challenge (DBPCFC)
Number of subjects: 15